If a marketing authorisation is granted, the Scottish Medicines Consortium (SMC) would welcome a submission for tovorafenib, however the decision on whether to submit a medicine for appraisal to the SMC, and the timing of that submission, is entirely for the pharmaceutical company that holds the marketing authorisation for the medicine to make.